CA
NZ
UK
AU
IND
US
Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares extended their advance in pre-market trading after the company confirmed the FDA granted both Regenerative Medicine Advanced Therapy and Fast Track designations to cemacabtagene ansegedleucel, known as cema-cel, its investigational allogeneic CAR T cell therapy. Allogene is a South …
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares advanced in pre-market trading after the company reported second-quarter results that topped Wall Street estimates on both revenue and earnings. Amneal is a Bridgewater, New Jersey-based diversified biopharmaceutical company operating through its Affordable Medicines, Specialty, and AvKARE segments, delivering …
Align Technology, Inc. (NASDAQ:ALGN) shares fell in pre-market trading despite the company reporting record second-quarter revenue, as investors focused on a soft forward outlook. Align is a Tempe, Arizona-based global medical device company that designs and markets the industry-leading Invisalign clear aligner system alongside …
Today's session delivered a broad, decisive rally across the healthcare and medtech complex. IQVIA Holdings (NYSE: IQV) was the standout, surging nearly 14% on heavy volume to break out to fresh highs, while Becton Dickinson (NYSE: BDX), Smith & Nephew (NYSE: SNN), Zimmer Biomet …
Tenon Medical (NASDAQ:TNON) is a micro-cap medical device maker built around a single clinical idea: a better way to fuse the sacroiliac joint. After a string of acquisitions and a jump in revenue, the company is trying to prove its expanded SI-joint platform can …
Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical-stage specialty pharmaceutical company betting that it can build a franchise out of rare, poorly served skin diseases. Its lead asset, QRX003, is racing toward a pivotal trial in Netherton syndrome, a genetic disorder with no approved therapy. A …
Soligenix (NASDAQ:SNGX) built its investment case on HyBryte, a light-activated therapy for a rare skin lymphoma. That case cracked at last closing, when an independent monitoring committee halted the confirmatory FLASH2 study for futility. For a pre-revenue micro-cap that had staked its clinical credibility …
Aprea Therapeutics (NASDAQ:APRE) is the kind of clinical-stage micro-cap that lives or dies on a single molecule. This summer, its oral WEE1 inhibitor APR-1051 delivered the sort of early Phase 1 signal that keeps small biotechs relevant: confirmed activity in advanced solid tumors alongside …
BioAtla, Inc. (NASDAQ:BCAB) entered 2026 as a cautionary tale in small-cap biotech. The clinical-stage cancer company, built around its Conditionally Active Biologics (CAB) platform, was hit with a Nasdaq delisting determination in February 2026, had its trading suspended, cut roughly 70% of its staff, …
ENDRA Life Sciences (NASDAQ:NDRA) sits at a crossroads familiar to clinical-stage micro-caps: a technology showing genuine promise, paired with a balance sheet that leaves little margin for error. At last closing, the company launched a formal review of strategic alternatives, hiring advisors to weigh …
Please wait processing your request...